



Quarterly Conference Call
Friday, November 8, 2019 | 2:00 p.m. – 3:00 p.m. ET

Call Participants

Gerd Clabaugh, Erin Epton, Joe Perz, Dawn Terashita, Wendy Bamberg, Stephanie Black, Michelle Cantu, Valerie Deloney, Kris Ehresmann, Angela Fritzing, Bonnie Herring, Kate Heyer, Waleed Javaid, Julie Marders, Martha Ngoh, Monica Schroeder, Laurie Schulte, Puja Shah, Maureen Tierney, Rick Wild.
Members' organizational affiliations are listed on page 3 in the call packet.

Welcome Remarks and CORHA Membership Updates (Gerd Clabaugh)

Gerd Clabaugh opened the call with welcome remarks to call participants and acknowledged the following new CORHA members:

- Erin Epton – CSTE, Governance Committee Co-Chair
- Maureen Tierney – CSTE
- Scott Harris – ASTHO
- Rick Wild – CMS

High-Level Guidance Update (Wendy Bamberg)

- Wendy Bamberg, the consultant leading the development of the High-Level Guidance provided a brief overview of that work.
- The CORHA High-Level Guidance, which is modeled after CIFOR's Guidelines will include 10 chapters and 2 supplements on HAI outbreak topics.
- The chapter-development process includes the development of chapter outlines by Wendy, the development of these chapter(s) by identified authors, the review of these chapters by identified reviewers and finally review and approval by the Governance Committee and CORHA members.
- The development process also includes key-informant interviews with SMEs from public health agencies and other stakeholder groups to inform the content of these chapters.
- A tentative deadline for the completion of this work is the summer of 2020.

Workgroup Updates

A workgroup product tracker is available on pages 6-7 in the call packet.

Detection and Reporting (Erin Epton)

- Group A Strep definitions and thresholds have been developed and are currently with a CDC SME for review. Following this review, Workgroup A will determine how to collaborate with Workgroup B to further develop this product.
- A collaborative model between Workgroups A and B to develop a combined influenza product will be piloted at the January in-person meeting.
- The Medical Product document is currently under review by Isaac Benowitz.

Investigation and Control (Puja Shah)

- The *C. auris* and CRE documents were sent to the full Council on October 17 for member votes. The voting deadline has been extended to December 2. Members can submit their [votes here](#).

- Workgroup B is also in the process of developing Group A Strep and NTM products.
- As mentioned in the workgroup A update, the workgroup plans to pilot the Influenza product as a collaborative effort with Workgroup A.

Policy (Maureen Tierney)

- The Policy Workgroup is in the process of submitting an abstract for the SHEA Decennial Conference. The abstract describes an overview of the workgroup's approach to develop the notification and disclosure framework and next steps for the development of that work.
- The notification and disclosure framework was shared with patient advocates and ethicists for feedback. Most of the feedback that was received suggested areas for clarification. The reviewers were generally supportive of this work. The workgroup plans to engage reporters to review the product next.
- The workgroup is also developing examples to supplement the framework and is deciding what examples to include and the appropriate format to present these examples.
- Maureen also commended the involvement of SHEA members whose input have been invaluable.

Lab (Angela Fritzinger)

- The Lab Workgroup held its kickoff call in October. The focus of that call was to determine how to best approach the workgroup charge of developing pathogen-specific products to complement other CORHA workgroup products.
- Wendy Bamberg joined the November Lab Workgroup call where she provided an overview of the High-Level Guidance and invited the workgroup to support the development of specific chapters. Following Wendy's presentation, the workgroup has re-prioritized their focus to develop laboratory-related chapter in the High-Level Guidance. The workgroup has created subgroups to develop smaller sections to form the full chapter. The tentative deadline for the completion of this chapter is February 2020.

Strategic Update (Laurie Schulte)

- Laurie Schulte gave a brief presentation on the strategic planning process to re-orient members on the process and next steps. Her presentation elaborated on three key steps in the process, which were: 1) Preparation, 2) Strategic discussions during dedicated sessions at the in-person CORHA meeting, and 3) Implementation support. *These presentation slides are available on pages 8-14 in the call packet.*

CORHA Updates and Reminders

AMR Challenge (Joe Perz)

- There were discussions at the last in-person meeting that CORHA's mission and work aligns with the CDC-led AMR Challenge. A statement outlining the nature of CORHA's commitment and work on the AMR Challenge was drafted, approved and submitted to CDC. View the statement on the [CDC](#) and [CORHA](#) websites. *The commitment statement is available on page 16 in the call packet.*

In-Person Meeting:

- The in-person meeting is scheduled for January 22-23 in Atlanta. Registration details are available [here](#).

Other HAI/AR-Related Work

CDC (Joe Perz)

- CDC efforts on AMR control and reduction include:
 - The AMR Challenge, which kicked-off at the United Nations in September.
 - The recently released [HAI Progress Report](#), which highlights improvements for pathogens including key pathogens CORHA is working on, e.g. there has been a 29% decrease in CDI infections in hospitals between 2015 – 2018.
 - The new [AR Threats Report](#) released on November 13.
 - Joe pointed out that CORHA's products and work relates and supports these efforts.

CALL PACKET

CORHA OVERVIEW

Founding Member Organizations

ASTHO	CSTE	CDC	NACCHO
Co-Managing Organizations			

Governance Committee

Gerd Clabaugh	Erin Epton	Joe Perz	Dawn Terashita
ASTHO	CSTE	CDC	NACCHO
Co-Chairs			

CORHA Membership Organizations

Organization/Agency	Representatives	Non-Voting Representatives
APHL	Jafar Razeq	Kelly Wroblewski
APIC	Linda Greene	
ASTHO	Gerd Clabaugh Kris Ehresmann Scott Harris	Kate Heyer Martha Ngoh Ashley Ottewell
CDC	Joe Perz Elizabeth Mothershed	
CSTE	Erin Epton Maureen Tierney	Monica Schroeder Puja Shah
NACCHO	Dawn Terashita Hillary Hanson	Lilly Kan Michelle Cantu
SHEA	Waleed Javaid	Valerie Deloney
CMS	Rick Wild (non-voting)	
FDA	Julia Marders (non-voting)	

Workgroups

	Detection and Reporting "A"	Investigation and Control "B"	Policy Workgroup	Lab Workgroup	Communications Task Force
Leads	Erin Epton Linda Greene	Waleed Javaid Dawn Terashita	Maureen Tierney Dawn Terashita Moon Kim	Jafar Razeq Dan Diekema	Bonnie Herring
Meeting Frequency	First Wednesday of every month at 3:00 p.m. ET	Third Friday of every month at 3:00 p.m. ET	Second Thursday of every month at 3:00 p.m. ET	First Monday of every month at 9:00 a.m. ET	Third Thursday of every month at 1:00 p.m. ET

Key Documents

CORHA Strategic Map
CORHA Bylaws and Operating Guidance
CORHA Workgroup to Publication Process
CORHA Product List and Tracker
CORHA Member Roster
CORHA Conference Presentations and Templates
CORHA Newsletter

Meetings


Two In-Person Meetings Annually (Next Meeting on January 22 – 23 in Atlanta)	Quarterly Calls Annually (February, May, August, November)
---	---

All documents referenced in this document are also [available on Basecamp](#)

HIGH-LEVEL GUIDANCE CHAPTERS

Preface	
Acknowledgments	
Chapter 1	Overview of the CORHA High-Level Guidance
Chapter 2	Fundamental Concepts of Healthcare-Associated Infections and Antimicrobial Resistant Pathogens Surveillance and Outbreak Response
Chapter 3	Planning and Preparation for Healthcare-Associated Infection and Antimicrobial Resistant Pathogen Outbreak Response
Chapter 4	Healthcare-Associated Infection and Antimicrobial Resistant Pathogen Outbreak Detection and Reporting
Chapter 5	Investigation and Control of Healthcare-Associated Infection and Antimicrobial Resistant Pathogen Outbreaks
Chapter 6	Laboratory Best Practices in Support of Healthcare-Associated Infection and Antimicrobial Resistant Pathogen Outbreak Response
Chapter 7	Special Consideration for Multi-Facility and Multi-Jurisdictional Outbreaks
Chapter 8	Legal Considerations for Reporting, Investigation, and Control of Healthcare-Associated Infection and Antimicrobial Resistant Pathogen Outbreaks
Chapter 9	Communications, Media, Public Reporting, Notification, and Disclosure
Chapter 10	Performance Indicators for Healthcare-Associated Infection and Antimicrobial Resistant Pathogen Outbreak Response
Supplement A	Medical Product Investigations
Supplement B	Infection Control Breach Investigations

CORHA Product-Specific Tracker




Product Details


Product	Workgroup	Status	Notes
<i>C. difficile</i> (ACH)/ (non ACH CDI)	Workgroup A	Workgroup Development	
GAS	Workgroup A	Workgroup Development	
Medical Devices and Products	Workgroup A	Workgroup Development	
CRE	Workgroup A	Graphic Editor (8/2019)	Draft posted to website on 9/5
NTM	Workgroup A	Graphic Editor (8/2019)	Draft posted to website on 9/5
<i>C. difficile</i>	Workgroup B	Council-approved in November 2018. Revised Spring-Summer 2019. GC re-approved 8/28/2019. Sent to Technical Editor 9/2019.	
CRE	Workgroup B	GC-approved with minor comments on 8/28/2019. Sent to Council for review and vote on 10/17/2019.	Voting link
<i>C. auris</i>	Workgroup B	GC-approved with minor comments on 8/28/2019. Sent to Council for review and vote on 10/17/2019.	Voting link
Influenza	WG A and B	Workgroup Development	
Medical Product-Related Assessment	Workgroup B	Graphic Editor (8/2019)	
Notification and Disclosure Guiding Principles	Policy	Workgroup Development	

CORHA 2019 Strategy Update Process

CORHA Strategy Update Process



Elements of the Strategic Map



CORHA Strategy Update Process

- Preparation: planning calls, session design, pre-work
- Strategy session:
 - Assessed progress with implementing the 2016-2019 strategic map
 - Evaluated the effectiveness of the map
 - Updated the map for 2020-2022

Highlights: Updated Strategic Map

- Revised the central challenge from “build capacity for” to “enhance capabilities of” public health and healthcare to improve outbreak detection, response, and prevention (e.g., CORHA provides intellectual resources)
- Determined that Strategic Priorities A (detection and reporting) and B (investigation and control) are still distinct – but their implementation should be better integrated

Highlights: Updated Strategic Map

- Ensured new workgroups (Policy, Lab, Communications taskforce) are represented in the map
- Evolved Strategic Priority C from an “uptake” focus to a “responsiveness” focus (“where the rubber meets the road”)
- Updated Strategic Priority D (Council effectiveness and sustainability) to reflect the current stage of the Council’s life cycle (no longer a start-up)
- Updated associated strategic objectives


CORHA Strategy Update Process

- Implementation support:
 - Planning (staff calls and individual GC interviews)
 - Prioritization and efficiency survey (results: time is an issue, do more with Strategic Priorities C and D)
 - Implementation planning webinars with Communications taskforce (Strategic Priority C), Governance Committee (Strategic Priority D)
 - Identify key results for the next year
 - Identify a path to achieving those results

CORHA
Strategic Map: 2020-2022

**Enhance Capabilities of Public Health
and Healthcare to Improve Outbreak
Detection, Response, and Prevention**

Draft
06/27/19



CORHA'S AMR CHALLENGE COMMITMENT

The Council for Outbreak Response: Healthcare-Associated Infections (HAIs) and Antimicrobial-Resistant (AR) Pathogens (CORHA) commits to improving practices and policies for detecting, reporting, investigating, and controlling HAI/AR outbreaks. CORHA commits to publishing and promoting thresholds, outbreak definitions, and investigation tools for pathogens such as carbapenem-resistant Enterobacteriaceae and *Candida auris*. In addition, CORHA commits to providing a forum for healthcare and public health partners to work together to improve communication such as patient notification and laboratory practices in support of HAI/AR response activities.